GILEAD SCIENCES, INC. - 13 Feb 2026 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: 10%+ Owner
Signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Issuer symbol: XLO
Transactions as of: 13 Feb 2026
Net transactions value: +$1,999,991
Form type: 4
Filing time: 17 Feb 2026, 17:31:38 UTC
Previous filing: 01 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GILEAD SCIENCES, INC.	10%+ Owner	333 LAKESIDE DRIVE, FOSTER CITY	Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson	17 Feb 2026	0000882095

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLO	Prefunded Warrants (right to buy)	Purchase	$1,999,991	+3,739,000	+10%	$0.5349	40,384,266	13 Feb 2026	Common Stock	3,739,000	$0.000100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

Content

The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.